Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
347 participants
INTERVENTIONAL
2025-12-02
2031-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Why is this study being done? This research study is for adults with a type of cancer called Malignant Peritoneal Mesothelioma (MPM). Currently, it is hard for doctors to know which treatment will work best for each patient after surgery. This study will test a new, personalized way to choose treatments using a model grown from a patient's own tumor in the lab, called a Patient-derived tumor-like cell cluster (PTC) model. The main goal is to see if using this PTC model to guide treatment can help patients live longer without their cancer getting worse, compared to a standard chemotherapy treatment.
Who can participate? Adults aged 18 and older with a specific type of MPM (epithelioid or biphasic) who are planned to have surgery and heated chemotherapy (CRS+HIPEC) and can provide a tumor sample for the PTC model may be eligible.
What will happen in the study?
* Participants will be randomly assigned to one of two groups by chance, like flipping a coin.
* Standard Treatment Group: This group will receive the standard chemotherapy combination of Gemcitabine, Oxaliplatin, and Apatinib.
* Personalized Treatment Group: This group will have a PTC model made from their tumor. The model will be tested with different drugs (chemotherapy, targeted therapy, and immunotherapy) in the lab. The treatment that works best on the model will be chosen for the patient.
* Both groups will receive their assigned treatment for 6 cycles.
* Participants will be followed for several years to see how they are doing, through clinic visits and scans.
What are the possible benefits? Participants in the personalized treatment group might receive a therapy that is more effective for their specific cancer. The information from this study may help doctors better treat future patients with MPM.
What are the possible risks? The risks include side effects from cancer treatments, which can include low blood cell counts, nausea, vomiting, high blood pressure, liver problems, and tiredness. There is also a risk that the PTC model may not grow successfully in the lab, or that the drug that works in the model may not work as well in the body. The study team will closely monitor all participants for any side effects and manage them promptly.
Who is paying for the study? This study is funded by the National Key R\&D Program of China.
Where is the study taking place? The study is conducted at multiple hospitals in China, including Beijing Tsinghua Changgung Hospital, Beijing Shijitan Hospital, and Cangzhou Central Hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
NCT06912152
Real World Study of MPM in China
NCT05042557
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
NCT05918107
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
NCT05136677
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
NCT06413212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group
PTC guided individualized treatment
According to the PTC drug sensitivity test, the types of chemotherapy combined with targeted and immune drugs were determined
Control Group
Standard chemotherapy regimens
According to the previous study, the patient received gemcitabine + oxaliplatin + apatinib standard treatment regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PTC guided individualized treatment
According to the PTC drug sensitivity test, the types of chemotherapy combined with targeted and immune drugs were determined
Standard chemotherapy regimens
According to the previous study, the patient received gemcitabine + oxaliplatin + apatinib standard treatment regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years or older.
* Histopathologically confirmed diagnosis of epithelioid or biphasic malignant peritoneal mesothelioma (MPM).
* Scheduled to undergo cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent adjuvant therapy.
* Availability of sufficient fresh tumor tissue sample obtained during surgery for Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
* Karnofsky Performance Status (KPS) score \> 60.
* Adequate hematologic function:
* White blood cell count ≥ 3.5 × 10⁹/L
* Platelet count ≥ 80 × 10⁹/L
* Adequate hepatic function:
* Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \< 2 × upper limit of normal (ULN)
* Adequate renal function:
* Serum creatinine \< 1.2 × ULN
* Adequate cardiac and pulmonary function to tolerate major surgery, as assessed by the investigator.
* Voluntarily agrees to participate by providing written informed consent and demonstrates good compliance.
Exclusion Criteria
* Presence of concurrent severe medical comorbidities that, in the investigator's judgment, preclude tolerance to the study treatment.
* Diagnosis of another active malignant tumor during the screening process, which may interfere with the study outcomes.
* Considered by the investigator to be unsuitable for participation in this study for any other reason (e.g., psychological, familial, or social factors).
* Unwillingness to accept the assigned treatment regimen or the required follow-up schedule.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Shijitan Hospital, Capital Medical University
OTHER
Cangzhou Central Hospital
OTHER
Beijing Tsinghua Chang Gung Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Li
Professor of Oncology and Director of the Department of Peritoneal Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tsinghua University affiliated Beijing Tsinghua Changgung Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25879-0-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.